Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall

被引:0
|
作者
G. Chinetti
J.-C. Fruchart
B. Staels
机构
[1] U.325 Inserm,
[2] Institut Pasteur de Lille,undefined
[3] 1,undefined
[4] rue Calmette BP245,undefined
[5] 59019 Lille,undefined
[6] France,undefined
[7] E-mail: bart.staels@pasteur-lille.fr,undefined
来源
Zeitschrift für Kardiologie | 2001年 / 90卷 / Suppl 3期
关键词
Key words Transcription factors – gene expression – macrophage – endothelial cell – smooth muscle cell; Abbreviations AP-1: activating protein-1; Apo: apolipoprotein; NFAT: nuclear factor of activated T cells; NSAIDs: non-steroidal antiinflammatory drugs; PPAR: peroxisome proliferator-activated receptor; PPRE: peroxisome proliferator response element; RXR: retinoid X receptor; STAT: signal transducer and activator of transcription.;
D O I
10.1007/s003920170034
中图分类号
学科分类号
摘要
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors which function as regulators of lipid and lipoprotein metabolism and glucose homeostasis and influence cellular proliferation, differentiation and apoptosis. PPARα is highly expressed in liver, muscle, kidney and heart, where it stimulates the β:-oxidative degradation of fatty acids. PPARγ is predominantly expressed in intestine and adipose tissue when it triggers adipocyte differentiation and promotes lipid storage. Recently, the expression of PPARα and PPARγ was also reported in cells of the vascular wall, such as monocyte/macrophages, endothelial and smooth muscle cells. The hypolipidemic fibrates and the antidiabetic glitazones are synthetic ligands for PPARα and PPARγ respectively. Furthermore, fatty acid-derivatives and eicosanoids are natural PPAR ligands: PPARα is activated by leukotriene B4, whereas prostaglandin J2 is a PPARγ ligand, as well as some components of oxidized LDL, such as 9- and 13-HODE. These observations suggested a potential role for PPARs not only in metabolic but also in inflammation control and, by consequence, in related diseases such as atherosclerosis. More recently, PPAR activators were shown to inhibit the activation of inflammatory response genes (such as IL-2, IL-6, IL-8, TNFα and metalloproteases) by negatively interfering with the NF-κB, STAT and AP-1 signalling pathways in cells of the vascular wall. Furthermore, PPARs may also control lipid metabolism in the cells of the atherosclerotic plaque. In addition, different clinical trials (such as the LOCAT, BECAIT and VA-HIT) as well as animal studies indicate that PPAR activators may have anti-atherogenic properties by reducing the progression of atherosclerotic lesions. In this review, we summarize the evidence indicating that PPARα and PPARγ directly modulate vessel wall functions, and its consequences in the control of cardiovascular disease.
引用
收藏
页码:125 / 132
页数:7
相关论文
共 50 条
  • [31] Peroxisome proliferator-activated receptors, orphans with ligands and functions
    Schoonjans, K
    Martin, G
    Staels, B
    Auwerx, J
    CURRENT OPINION IN LIPIDOLOGY, 1997, 8 (03) : 159 - 166
  • [32] Discovery of ligands for the nuclear peroxisome proliferator-activated receptors
    Willson, TM
    Lehmann, JM
    Kliewer, SA
    PEROXISOMES: BIOLOGY AND ROLE IN TOXICOLOGY AND DISEASE, 1996, 804 : 276 - 283
  • [33] Peroxisome proliferator-activated receptors: Nuclear control of metabolism
    Desvergne, B
    Wahli, W
    ENDOCRINE REVIEWS, 1999, 20 (05) : 649 - 688
  • [34] Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
    Guan, YF
    Breyer, MD
    KIDNEY INTERNATIONAL, 2001, 60 (01) : 14 - 30
  • [35] Peroxisome Proliferator-Activated Receptors (PPARs) and the Human SkinImportance of PPARs in Skin Physiology and Dermatologic Diseases
    Pit Sertznig
    Markus Seifert
    Wolfgang Tilgen
    Jöorg Reichrath
    American Journal of Clinical Dermatology, 2008, 9 : 15 - 31
  • [36] Peroxisome Proliferator-Activated Receptors (PPARs) levels in spermatozoa of normozoospermic and asthenozoospermic men
    Mousavi, Motahareh Sadat
    Shahverdi, Abdolhossein
    Drevet, Joel
    Akbarinejad, Vahid
    Esmaeili, Vahid
    Sayahpour, Forough Azam
    Topraggaleh, Tohid Rezaei
    Rahimizadeh, Pegah
    Alizadeh, AliReza
    SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE, 2019, 65 (06) : 409 - 419
  • [37] Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics?
    Gupta, Mrinal
    Mahajan, Vikram K.
    Mehta, Karaninder S.
    Chauhan, Pushpinder S.
    Rawat, Ritu
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2015, 307 (09) : 767 - 780
  • [38] Peroxisome Proliferator-Activated Receptors (PPARs) and Oxidative Stress in Physiological Conditions and in Cancer
    Muzio, Giuliana
    Barrera, Giuseppina
    Pizzimenti, Stefania
    ANTIOXIDANTS, 2021, 10 (11)
  • [39] Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy
    Gou, Qian
    Gong, Xin
    Jin, Jianhua
    Shi, Juanjuan
    Hou, Yongzhong
    ONCOTARGET, 2017, 8 (36) : 60704 - 60709
  • [40] Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes
    Cristiano, L
    Bernardo, A
    Cerù, MP
    JOURNAL OF NEUROCYTOLOGY, 2001, 30 (08): : 671 - 683